These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27634311)

  • 21. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis.
    Tanaka Y
    Curr Opin Rheumatol; 2012 May; 24(3):319-26. PubMed ID: 22388646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Discontinuation of immunosuppressive and immunomodulatory drugs in connective tissue diseases].
    Targońska-Stępniak B
    Wiad Lek; 2015; 68(3):265-70. PubMed ID: 26753211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
    Tanaka Y; Hirata S
    Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current concepts in the management of rheumatoid arthritis.
    Tanaka Y
    Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center.
    Kaltsonoudis E; Pelechas E; Voulgari PV; Drosos AA
    Semin Arthritis Rheum; 2019 Feb; 48(4):597-602. PubMed ID: 30075990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis.
    Cavalli G; Favalli EG
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1313-1322. PubMed ID: 31663390
    [No Abstract]   [Full Text] [Related]  

  • 27. The BeSt way of withdrawing biologic agents.
    Allaart CF; Lems WF; Huizinga TW
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S14-8. PubMed ID: 24129130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Rheumatoid arthritis].
    Aletaha D; Kerschbaumer A
    Z Rheumatol; 2017 Feb; 76(1):8-14. PubMed ID: 28058499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs.
    Tanaka Y
    Rheumatology (Oxford); 2021 Dec; 60(Suppl 6):vi12-vi20. PubMed ID: 34951925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there a place for initial treatment with biological DMARDs in the early phase of RA?
    Nam JL; Emery P
    Best Pract Res Clin Rheumatol; 2013 Aug; 27(4):537-54. PubMed ID: 24315053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose reduction of biologic therapy in inflammatory arthritis: A qualitative study of patients' perceptions and needs.
    Hewlett S; Haig-Ferguson A; Rose-Parfitt E; Halls S; Freke S; Creamer P
    Musculoskeletal Care; 2019 Mar; 17(1):63-71. PubMed ID: 30398699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study.
    Addimanda O; Marino M; Farina I; Trevisani M; Arrigoni E; Lumetti F; Crescentini F; Sambo P; Bezzi A; Bruschi M; Santilli D; Reta M; Bosi S; Delsante G; Girelli F; Montaguti L; Meliconi R; Sebastiani M; Ferri C; Malavolta N; Govoni M; Trombetti S; De Palma R; Salvarani C
    Clin Exp Rheumatol; 2017; 35(2):201-208. PubMed ID: 28134078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis.
    Martin-Martin LS; Giovannangeli F; Bizzi E; Massafra U; Ballanti E; Cassol M; Migliore A
    Drug Des Devel Ther; 2017; 11():985-994. PubMed ID: 28408798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of conventional disease-modifying anti-rheumatic drugs in established RA.
    Jurgens MS; Jacobs JW; Bijlsma JW
    Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):523-33. PubMed ID: 22137922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity.
    Ye W; Tucker LJ; Coates LC
    Drugs; 2018 Nov; 78(16):1705-1715. PubMed ID: 30341684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.
    van Vollenhoven RF; Østergaard M; Leirisalo-Repo M; Uhlig T; Jansson M; Larsson E; Brock F; Franck-Larsson K
    Ann Rheum Dis; 2016 Jan; 75(1):52-8. PubMed ID: 25873634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of progressively reducing biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in persistent remission: a study protocol for a non-inferiority randomized, controlled, single-blind trial.
    Lei S; Li Z; Zhang X; Zhou S
    Trials; 2022 Jul; 23(1):600. PubMed ID: 35897052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission.
    Alivernini S; Peluso G; Fedele AL; Tolusso B; Gremese E; Ferraccioli G
    Arthritis Res Ther; 2016 Feb; 18():39. PubMed ID: 26842890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search.
    Verhoef LM; Tweehuysen L; Hulscher ME; Fautrel B; den Broeder AA
    Rheumatol Ther; 2017 Jun; 4(1):1-24. PubMed ID: 28255897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
    Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
    J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.